The Global Health Body Sounds Alert Over Critical Scarcity of Obesity Injections
Under 10% of patients who could benefit from GLP-1 drugs such as Wegovy have access to them, caution the global health agency as it releases its initial advice on the therapies.
With more than one billion people worldwide currently obese, it is advocating for more widespread and fairer access to GLP-1 medication.
Per projections, more than two billion will be living with obesity by 2030 unless action is taken.
"The new guidance acknowledges that excess weight is a long-term condition that can be addressed with thorough and continuous treatment," remarked the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and distribution challenges are key obstacles to broad availability to the injections that can help people shift considerable weight, explains the body.
Skinny Jab Scarcity
Even under the present best projected case, the supply of such drugs would only suffice for about 100 million people – fewer than 10% of the global need, as stated by the health organization.
The advice urges governments and firms to increase availability, via measures like voluntary licensing.
Exclusive production rights on a key compound – the primary ingredient of the drug Wegovy – is scheduled to end in multiple nations in 2026.
The Way Weight-Loss Drugs Function
The injections imitate a natural hormone to delay gastric emptying, curb appetite and boost feelings of fullness so people reduce food intake.
People usually begin shedding pounds in the initial weeks of commencing the regular doses.
Evidence suggests users may see weight return a year later of discontinuing the drug, as their typical appetite return.
To be overweight or obese raises your likelihood for experiencing health problems, such as type 2 diabetes, cardiovascular issues, brain attack, and specific cancers.
Obesity affects people in all nations and was responsible for over three and a half million fatalities worldwide in 2024, as per the health agency.
